Galapagos N.V. (NASDAQ:GLPG) Q1 2026 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to Galapagos's Q1 2026 Financial Results Conference Call.
Galapagos Nv (GLPG)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 407,800 | $12,225,844 | +30% | 0.02% |
| 2. | Marshall Wace LLP Paul Marshall And Ian Wace | 32,399 | $971,321 | 0% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,707,477 | $500,157,715 | 30.34% | |
| 2. | 338,152 | $10,137,797 | 0% | |
| 3. | 168,148 | $5,041,077 | 0% | |
| 4. | 76,879 | $2,304,832 | 0% | |
| 5. | 65,523 | $1,964,380 | 0.01% |
News See All
RBC Cuts Galapagos NV (GLPG) Price Target to $28, Maintains Sector Perform Ahead of Q1
TheFly reported on April 7 that RBC Capital Markets adjusted its outlook on GLPG, reducing its price target from $33 to $28 while maintaining a Sector Perform rating.
9 Most Undervalued Healthcare Stocks to Buy Now
On April 17, Matt Powers, managing partner at Powers Advisory Group, appeared on CNBC’s Squawk Box to discuss the forces shaping current market behavior.
7 Fastest Growing European Stocks to Invest In
European stocks are getting a closer look again, and not only because investors want to diversify away from a crowded U.S. trade.
Galapagos N.V. (NASDAQ:GLPG) Q4 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Galapagos Year-End 2025 Financial Results Conference Call.
Galapagos N.V. (NASDAQ:GLPG) Q3 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Galapagos Third Quarter 2025 Financial Results Conference Call.
Galapagos NV (GLPG)’ CAR-T Therapy Hits 97% Response Rate in Lymphoma Trial
Galapagos NV (NASDAQ:GLPG) is a Belgian-based firm and is carving out a leading position in next-generation oncology through its CAR-T programs and decentralized manufacturing model, designed to deliver...
11 Best Performing Biotech Stocks So Far in 2025
On July 8, Jared Holz of Mizuho spoke on CNBC's "Closing Bell Overtime" about whether the biotech sector is ready for a breakthrough.
Galapagos NV (NASDAQ:GLPG) Q1 2025 Earnings Call Transcript
Operator: Good day! And thank you for standing by. Welcome to the Galapagos First Quarter 2025 Financial Results and Business Update. At this time all participants are in a listener-only mode.
Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn
Wall Street has come down crashing on President Donald Trump’s sweeping tariffs, raising the risk of a trade war that could push the global economy into recession.
Hedge Fund Resource Center